Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee
Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee


Regulatory News:



Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.

Vifor Pharma Group Reports Continued Growth in H1 2020
Vifor Pharma Group Reports Continued Growth in H1 2020


Regulatory News:



Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect

Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter
Vifor Pharma Gruppe wächst auch im 1. Halbjahr 2020 weiter


Regulatory News:



Die Vifor Pharma Gruppe ist trotz der Herausforderungen, die Patienten auch während der COVID-19-Pandemie zu erreichen, im 1. Halbjahr 2020 weiter gewachsen. Die Finanzprognose

VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005052/en/



Vifor Fresenius Medical Care Renal Pharma (VFMCRP)

92. Generalversammlung der Vifor Pharma Gruppe
92. Generalversammlung der Vifor Pharma Gruppe


Regulatory News:



An der 92. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt.



Aufgrund der aktuellen Situation und im

92nd Vifor Pharma Group Annual General Meeting
92nd Vifor Pharma Group Annual General Meeting


Regulatory News:



At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors.



In view of the current situation

Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients
Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients


Regulatory News:



Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes

BB Biotech: So geht Rendite mit COVID-19-Aktien!
BB Biotech: So geht Rendite mit COVID-19-Aktien!

Interessante Einblicke in den Geschäftsverlauf im Auftaktquartal liefert heute BB Biotech (WKN: A0NFN3). Die mussten zwar Rückschläge einstecken, glänzten aber auch durch Überraschungen – die mit

Update on 92nd Vifor Pharma Ltd. Annual General Meeting
Update on 92nd Vifor Pharma Ltd. Annual General Meeting


Regulatory News:



Vifor Pharma confirmed that it will hold its Annual General Meeting (AGM) on 14 May, 2020, as planned. In view of the current situation and based on Art. 6a of Ordinance 2

Update zur 92. Generalversammlung der Vifor Pharma AG
Update zur 92. Generalversammlung der Vifor Pharma AG


Regulatory News:



Vifor Pharma hat bestätigt, dass die Generalversammlung des Unternehmens wie geplant am 14. Mai 2020 abgehalten wird. Aufgrund der aktuellen Situation und im Einklang mit Art. 6a

Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance


Regulatory News:



Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The

Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose
Vifor Pharma Gruppe erzielt 2019 starkes Wachstum und übertrifft die angehobene Prognose


Regulatory News:



Die Vifor Pharma Gruppe erzielte 2019 ein starkes finanzielles und operatives Ergebnis dank Fokus auf die drei strategischen Wachstumstreiber und gezielten Investitionen in die

Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings


Regulatory News:



Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment

Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron portfolio


Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest

BB Biotech: Ausschau nach „lukrativen Anlagechancen“
BB Biotech: Ausschau nach „lukrativen Anlagechancen“

BB Biotech (WKN: A0NFN3) publiziert heute seine ersten Zahlen für das abgelaufene Geschäftsjahr. Aktionäre können sich freuen, denn als Dividende will die Schweizer Gesellschaft 3,40 CHF pro Aktie

Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously
Vifor Pharma raises awareness on Iron Deficiency Day 2019 for people around the world to take iron seriously


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005728/en/



Iron Deficiency Day is an international event which

Vifor Pharma Appoints Lee Heeson as President International and Member of the Executive Committee
Vifor Pharma Appoints Lee Heeson as President International and Member of the Executive Committee


Regulatory News:



Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020.



Lee Heeson joins Vifor

Vifor Pharma and Evotec form joint venture for early development in nephrology
Vifor Pharma and Evotec form joint venture for early development in nephrology


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105005841/en/



Vifor Pharma and Evotec SE today announced the

Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen


Regulatory News:



Vifor Pharma today announced a commercial partnership with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly

BB Biotech: Kurzfristige, temporäre Schwäche kaufenswert
BB Biotech: Kurzfristige, temporäre Schwäche kaufenswert

Der Schweizer Biotechnologie-Investor BB Biotech (WKN: A0NFN3) hat heute seine aktuellen Quartalszahlen vorgelegt. Demnach wurde in den ersten neun Monaten des laufenden Geschäftsjahres 2019 ein

Santhera: Vamorolone droht zu scheitern – an der Konkurrenz!
Santhera: Vamorolone droht zu scheitern – an der Konkurrenz!

Große Hoffnung setzen Anleger von Santhera (WKN: A0LCUK) in den einlizenzierten DMD-Medikamentenkandidaten Vamorolone und übersehen dabei offensichtlich völlig: Das Steroid wird in Zukunft

Can Marijuana Cure Alzheimer's Disease?
Can Marijuana Cure Alzheimer's Disease?
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of Aβ amyloid plaques and twisted tangles of a protein called "tau" in regions of the brain responsible for....
Why Advanced Accelerator Applications SA Acquired a Higher Price Today
Why Advanced Accelerator Applications SA Acquired a Higher Price Today
Advanced Accelerator Applications (NASDAQ: AAAP) is up 10.5% at 11:42 a.m. EDT after announcing that it was being acquired by Novartis (NYSE: NVS) for approximately $3.9 billion.Advanced....